Ridge Bio

Ridge Bio, also known as Ridge Biotechnologies, is a biotechnology company that leverages artificial intelligence and high-throughput, cell-free experimentation to design precision enzymes and targeted drug delivery systems. The company's proprietary platform integrates machine learning models with advanced wet-lab bioengineering to address complex challenges in drug development, including the creation of antibody-drug conjugates (ADCs), in vivo CAR-T therapies, targeted nucleic acid delivery, and catalytic medicines. Ridge Bio’s initial product pipeline features NativeLink enzymes, which allow for site-specific modification of therapeutic proteins without requiring changes to existing cell lines or manufacturing processes, and ProTrigger linkers, which are protease-cleavable prodrug systems engineered to activate therapeutic payloads specifically within the tumor microenvironment.

These technologies are designed to help pharmaceutical partners overcome significant hurdles in drug development, such as off-target toxicity, stability issues, and limitations in binding-based mechanisms of action. By enabling safer and more precise therapies, Ridge Bio aims to address unmet clinical needs across a range of therapeutic areas. Headquartered in Palo Alto and supported by investors including Sutter Hill Ventures, the company operates at the intersection of computational biology and experimental science to develop a new class of enzyme-based therapeutics. Their approach is focused on accelerating the discovery and development of next-generation medicines that provide improved efficacy and safety for patients.